Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy

Pathologic Response and Survival Outcomes on HER2-Low vs. HER2-Zero in Breast Cancer Receiving Neoadjuvant Chemotherapy

<i>Background and Objectives</i>: The clinical value of HER2-low breast cancer (BC), defined by immunohistochemistry (IHC) scores of 1+ or 2+/ISH-negative without HER2 amplification, remains unclear in the neoadjuvant setting. This study aimed to determine whether HER2-low and HER2-zero...

Full description

Saved in:
Bibliographic Details
Main Authors: Rumeysa Colak, Caner Kapar, Ezgi Degerli, Seher Yildiz Tacar, Aysegul Akdogan Gemici, Nursadan Gergerlioglu, Serdar Altinay, Mesut Yilmaz
Format: Article
Language:English
Published: MDPI AG 2025-06-01
Series:Medicina
Subjects:
HER2-low
breast cancer
neoadjuvant chemotherapy
pathologic complete response
disease-free survival
hormone receptor status
Online Access:https://www.mdpi.com/1648-9144/61/7/1168
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items